|
|
|
R E S O L U T I O N
|
|
WHEREAS, Dr. David Wang is being honored by the VA North |
|
Texas Health Care System as its Researcher of the Year on May 16, |
|
2019; and |
|
WHEREAS, Dr. Wang serves as a staff medical oncologist for |
|
the VA North Texas Health Care System as well as an associate |
|
professor of internal medicine at The University of Texas |
|
Southwestern Medical Center in Dallas; he holds an undergraduate |
|
degree from Asbury College, a medical degree from Vanderbilt |
|
University, and a graduate degree in cellular and molecular |
|
medicine from Johns Hopkins University; while in medical school, he |
|
was selected as a Howard Hughes Medical Institute-National |
|
Institutes of Health Research Scholar, and he notably performed |
|
research at the National Cancer Institute; he went on to complete |
|
his residency in internal medicine on the Osler Medical Service of |
|
Johns Hopkins and his medical oncology fellowship at the Sidney |
|
Kimmel Comprehensive Cancer Center at Johns Hopkins; and |
|
WHEREAS, Among his most significant accomplishments, |
|
Dr. Wang has been part of a lab group that has made breakthroughs in |
|
understanding Barrett's esophagus, a condition that can be a |
|
precursor to esophageal cancer; his lab has also focused its |
|
research efforts on developing biomarkers and molecularly targeted |
|
therapy strategies for esophageal cancer; these studies have been |
|
funded by grants awarded by the U.S. Department of Veterans |
|
Affairs, the American Cancer Society, and the National Institutes |
|
of Health; and |
|
WHEREAS, As a clinically active oncologist, Dr. Wang was |
|
instrumental in establishing a multidisciplinary GI malignancy |
|
clinic at the Dallas VA Medical Center, and he serves as the |
|
principal investigator for many of its clinical trials; he is also |
|
the oncology team leader for the UT Southwestern Esophageal |
|
Diseases Center, a member of the national VA GI Clinical Trials |
|
Steering Committee, and a member of the Via Pathways GI Cancer |
|
clinical guidelines panel; his other professional affiliations |
|
include the American Gastroenterological Association, the American |
|
Association for Cancer Research, and the American Society of |
|
Clinical Oncology; and |
|
WHEREAS, Dr. David Wang has distinguished himself through |
|
his professional achievements and his commitment to the advancement |
|
of research with lifesaving potential, and his efforts have |
|
contributed greatly to the mission of the VA North Texas Health Care |
|
System; now, therefore, be it |
|
RESOLVED, That the House of Representatives of the 86th Texas |
|
Legislature hereby congratulate Dr. David Wang on being named the |
|
VA North Texas Health Care System's 2019 Researcher of the Year and |
|
extend to him sincere best wishes for continued success with his |
|
important work; and, be it further |
|
RESOLVED, That an official copy of this resolution be |
|
prepared for Dr. Wang as an expression of high regard by the Texas |
|
House of Representatives. |